Compare COEP & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COEP | SACH |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 52.0M |
| IPO Year | N/A | 2017 |
| Metric | COEP | SACH |
|---|---|---|
| Price | $15.70 | $1.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 74.3K | ★ 181.0K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 18.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $500,996.00 | ★ $3,906,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $0.80 |
| 52 Week High | $21.41 | $1.48 |
| Indicator | COEP | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 57.96 |
| Support Level | $15.40 | $1.00 |
| Resistance Level | $16.80 | $1.08 |
| Average True Range (ATR) | 1.57 | 0.05 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 20.64 | 72.22 |
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.